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Abstract
Background: We previously showed that beta-amyloid (Ab), a peptide considered as relevant to Alzheimer’s Disease, is able
to act as a neuromodulator affecting neurotransmitter release in absence of evident sign of neurotoxicity in two different rat
brain areas. In this paper we focused on the hippocampus, a brain area which is sensitive to Alzheimer’s Disease pathology,
evaluating the effect of Ab (at different concentrations) on the neurotransmitter release stimulated by the activation of pre-
synaptic cholinergic nicotinic receptors (nAChRs, a4b2a n da7 subtypes). Particularly, we focused on some
neurotransmitters that are usually involved in learning and memory: glutamate, aspartate and GABA.
Methodology/Findings: We used a dual approach: in vivo experiments (microdialysis technique on freely moving rats) in
parallel to in vitro experiments (isolated nerve endings derived from rat hippocampus). Both in vivo and in vitro the
administration of nicotine stimulated an overflow of aspartate, glutamate and GABA. This effect was greatly inhibited by the
highest concentrations of Ab considered (10 mM in vivo and 100 nM in vitro). In vivo administration of 100 nM Ab (the
lowest concentration considered) potentiated the GABA overflow evoked by nicotine. All these effects were specific for Ab
and for nicotinic secretory stimuli. The in vitro administration of either choline or 5-Iodo-A-85380 dihydrochloride (a7 and
a4b2 nAChRs selective agonists, respectively) elicited the hippocampal release of aspartate, glutamate, and GABA. High Ab
concentrations (100 nM) inhibited the overflow of all three neurotransmitters evoked by both choline and 5-Iodo-A-85380
dihydrochloride. On the contrary, low Ab concentrations (1 nM and 100 pM) selectively acted on a7 subtypes potentiating
the choline-induced release of both aspartate and glutamate, but not the one of GABA.
Conclusions/Significance: The results reinforce the concept that Ab has relevant neuromodulatory effects, which may span
from facilitation to inhibition of stimulated release depending upon the concentration used.
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Introduction
In 1984 Glenner and Wong sequenced a small peptide isolated
from the brains of Alzheimer’s disease (AD) patients. This peptide,
known as beta-amyloid (Ab), was subsequently recognized as the
main pathogenetic marker of AD [1]. The increased levels of the
peptide in extracellular sites lead to subsequent events that include
the aggregation and deposition of Ab, the hyperphosphorylation of
tau protein, the occurrence of neurotoxic phenomena and
consequent neuronal death and, finally, dementia [2,3].
Although the neurotoxic role of Ab is unchallenged, the
scientific community has emphasized the existence of physiological
roles for the peptide (as reviewed in [4]). The idea is that Ab may
be important in normal brain functioning, but when it exceeds
certain concentrations the peptide may become neurotoxic. Both
different aggregates and isoforms of Ab may have different
biological actions in a continuum from physiology to pathology
determining and participating to the subsequent stages of the
disease [4]. In this regard, we previously showed that Ab acts as a
neuromodulator, affecting neurotransmitter release in the absence
of evident signs of neurotoxicity [5–7]. This role may be at
borderline between physiology and pathology. In a physiological
context, the neuromodulatory role of Ab would be important for
the proper balance among neurotransmitter systems. On the
contrary, in pathological conditions the Ab-mediated synaptic
modulation might be related to Ab-driven functional alterations of
neurotransmission in addition and before the well known
neurodegenerative events. The dysregulation of neurotransmission
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29661may in turn produce early cognitive and non-cognitive distur-
bances based on the neurotransmitter systems and the brain area
involved.
For all these reasons, we started to systematically explore the
effect of the peptide on different brain areas and neurotransmitter
systems both in vivo and in vitro. Our previous studies showed that
Ab inhibits the cholinergic control of both dopamine and c-
aminobutyric acid (GABA) release in the nucleus accumbens and
caudate putamen [5–7]. In these brain areas, Ab affects
neurotransmitter release acting downstream muscarinic receptors,
particularly on protein kinase C [5].
The purpose of the present study is to evaluate whether
nicotinic acetylcholine receptors (nAChRs) may also be involved in
the neuromodulatory action of Ab. In this regard, several findings
suggest that Ab interacts with high affinity with nAChRs. The
peptide can bind to a7 and with 100–5000 times lower affinity to
a4b2 nAChRs [8]. Interestingly, the Ab-nAChRs interaction may
serve non-neurotoxic roles (as the control of synaptic plasticity and
neuronal homeostasis), as well as contributing to AD etiology [9].
There are conflicting data concerning the type of effect exerted
by Ab on nAChRs, with some authors showing the activation of
the receptor, whereas others report an antagonist action [10].
These differences may be related either to the experimental model
investigated or to the Ab species and concentrations administered
[11].
An intriguing brain area for the purpose of this study is the
hippocampus, a neuroanatomical structure that is implicated in
learning and memory and that is involved in AD from the early
stages of the disease [12]. Cholinergic projections to the
hippocampus mainly derive from the medial septum-diagonal
band via the fimbria fornix [13,14]. Acetylcholine released from
these projections acts on both muscarinic and nicotinic targets
modulating neurotransmission [15,16]. Interestingly, we recently
demonstrated that the activation of both a7 and a4b2 nAChRs
subtypes promotes the hippocampal release of inhibitory and
excitatory neurotransmitters such as GABA, glutamate (Glu), and
aspartate (Asp) [17,18] This cholinergic control of GABAergic and
glutamatergic systems may have important effects concerning the
intra-hippocampal circuits modulating synaptic plasticity, a
process relevant to memory trace formation [19]. Moreover, a
putative modulatory effect of Ab on excitatory and inhibitory
transmitters may be relevant in the derangements of synaptic
activity preceding and accompanying neurodegenerative processes
associated with Ab deposition in the course of the disease.
We used only Ab1–40 peptide in our experiments, for two main
reasons. First, physiologically the 40-amino-acid long peptide is
the most abundant form [20–22]. Second, Ab1–42 has been
reported to aggregate faster than Ab1–40 [23] and thus it is
considered as the most neurotoxic species [24]. With the aim of
exploring new effects of Ab other than the neurotoxic ones, we
chose to avoid this potentially confounding element.
For all these reasons, using both in vivo (microdialysis) and in vitro
(synaptosomes in superfusion) techniques, we studied whether
Ab1–40 (pM-mM) may affect the nicotine (Nic)-evoked release of
GABA, Glu and Asp in hippocampus. In particular, we evaluated
whether the neuromodulatory action of Ab may be exerted on
both a7 and a4b2 nAChRs subtypes.
The results presented here show the Ab capability to regulate
the nicotinic control of aspartate, glutamate and GABA release in
absence of evident signs of neurotoxicity, and in a way that
depends upon the concentration used and the nicotinic receptor
subtype involved.
Results
In vivo results
We first performed immunohistochemical analysis in order to
test whether the administration of Ab1–40 through the dialysis
probe allowed the delivery of the peptide to the tissue. Fig. 1 shows
the presence of the peptide for all the concentrations tested
(100 nM–10 mM) within the hippocampus. As expected, there was
a visible positive correlation between the concentration adminis-
tered and the signal of Ab immunoreactivity in the tissue.
We characterized the Ab peptide conformation by using
Western Blot procedure, starting from the stock solution
(100 mMA b1–40 solution). With SDS-PAGE, all Ab1–40
preparations analyzed resolved to immunoreactive species consis-
tent with Ab monomer (Fig. S1).
We then analyzed the effect of an acute administration of Nic
on the release of GABA, Glu, and Asp in hippocampus in vivo.
Figure 1. Immunohistochemical analysis showing beta-amyloid
(Ab) content in hippocampal tissue after its administration at
different concentrations. Coronal section indicating the location of
the probe (hippocampus, black rectangle) counterstained with Mayer
Hematoxylin and relative fluorescence micrographs of the area within
the black rectangle showing the presence of human Ab protein. Ab
immunoreactivity (red-PE staining, white arrows) immediately after
perfusion of 10 mM, 1 mM and 100 nM Ab1–40. Nuclear DNA was
counterstained with Hoechst 33342 (blue staining). Scale bars for Mayer
hematoxylin sections: 200 mm. Scale bars for fluorescent micrographs:
125 mm.
doi:10.1371/journal.pone.0029661.g001
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microdialysis of 20 mM Nic is not enough to evoke a GABA
overflow in hippocampus [25]. In similar experimental conditions
Toth [26] showed that 50 mM Nic is able to significantly increase
the levels of Glu and Asp in hippocampal extracellular
compartment. Despite Toth [26] was able to obtain a substantial
release using lower concentrations, in our in vivo experiments the
preliminary concentration curve performed (not shown) indicated
50 mM Nic as the best working condition. Hence, we evaluated
50 mM Nic. It should be stressed that microdialysis application of
drugs can be considered as a point source in the brain, having a
sphere of action with decreasing drug concentration. The effective
concentrations used in the in vivo experiments cannot be specified;
hence the concentration in the probe was given. Therefore the
current drug concentration could be supraphysiological [27].
Future experiments comparing other administration methods may
help to provide insight on this aspect.
In our experimental conditions a 40 minutes-long administra-
tion of 50 mM Nic was able to greatly enhanced GABA release
from basal values. The effect of Nic peaked after 20 minutes of
perfusion (1321%, Fig. 2A inset) and persisted for additional
20 minutes after the end of the treatment (+742% compared to
basal values, Fig. 2A inset). Moreover, a 40 minutes-long
treatment with 50 mM Nic was also effective in stimulating the
release of excitatory amino acids, thus supporting the previously
published data. Concerning Glu, the peak effect of Nic was
observed at the end of the treatment (61%), then the release
returned to the basal level (Fig. 2B inset). The time course of the
endogenous Asp release evoked by Nic (50 mM) in vivo is reported
in the inset to Fig. 2C. The effect of Nic on Asp release reached the
top at the end of the perfusion with Nic (190%).
Based on the previously described time courses, we analyzed the
effect of Nic exposure on the cumulative amount of neurotrans-
mitter released over time, calculating the area under the curve
(AUC). Then, we compared the average AUC after 50 mM Nic
exposure to the average AUCs obtained after the separate
administration of Nic in co-perfusion with Ab1–40. Particularly,
we created a dose-response curve evaluating different concentra-
tions of the peptide (100 nM–10 mM). The Nic-evoked GABA
overflow was inhibited by 10 mMA b1–40 (59%) and potentiated
by 100 nM Ab1–40 (35%) (Fig. 2A). Concerning 1 mMA b1–40
(the middle concentration evaluated in vivo), there was a trend to
exert an inhibitory effect which, however, did not reach the
statistical significance (Fig. 2A). As far as excitatory neurotrans-
mitters, 10 mMA b1–40 was able to inhibit the Nic-induced
overflow of both Glu (57%, Fig. 2B) and Asp (38%, Fig. 2C). Also
1 mMA b1–40 impaired the Nic-induced overflow of both Glu
(70%) and Asp (61%), whereas 100 nM Ab1–40 was ineffective
(Fig. 2B and 2C). The reverse peptide Ab40–1 (tested at 10 mM)
did not modify the Nic-induced release of GABA (Fig. 2A), Glu
(Fig. 2B) and Asp (Fig. 2C). None of the concentrations of Ab1–40
tested in vivo (100 nM, 1 mM and 10 mM) affected the basal level of
GABA, Glu and Asp in the hippocampus (Fig. S2).
In order to evaluate whether the effects of Ab1–40 were
selective for the nicotinic control of neurotransmitter release, we
chose veratridine (Ver) as another secretory stimulus. Based on
previous microdialysis publications [28,29], we evaluated two
different concentrations for this depolarizing stimulus. As shown in
Fig. 3A–3C insets, 100 mM Ver elicited the release of the three
neurotransmitters studied although to a different extent
(GABA=1253%; Glu=170%; Asp=309%). The lower concen-
tration of Ver (50 mM) was able to elicit the release of GABA
(615%) but not the one of Glu and Asp. For these reasons we used
100 mM Ver in the following experiments. We then evaluated the
effect of Ab1–40 at 100 nM and 10 mM (the lowest and highest
concentration that had been considered in vivo, respectively) on the
release of neurotransmitters evoked by 100 mM Ver, comparing
the specific AUC. Both of these two concentrations of Ab1–40 did
not affect the Ver-induced overflow of GABA, Glu, and Asp
(Fig. 3A, Fig. 3B and Fig. 3C, respectively).
In vitro results
Likewise, Nic was able to evoke an overflow of GABA, Glu, and
Asp from hippocampal nerve endings in vitro experiments.
Figures 4A, 4B, and 4C respectively show the time course of the
endogenous GABA, Glu, and Asp release enhanced by 100 mM
Nic. Concerning GABA release, the peak effect (60%) of the
nicotinic agonist was observed at the end of the 90 s-long
treatment. In the case of both Asp and Glu the maximal effect
of Nic (60% and 50% respectively) was reached in fraction 41
(about 3 minutes after having stimulated the synaptosomes with
the cholinergic agonist), after which the release returns to the basal
level.
Figures 4A, 4B, and 4C also show that the presence of Ab1–40
in the medium of perfusion did not modify basal release of all three
selected neurotransmitters.
We then evaluated the effects of different concentrations of
Ab1–40 (from 100 pM up to 100 nM) on the Nic-evoked overflow
of GABA, Glu, and Asp. Fig. 5 shows that the highest
concentration of Ab1–40 tested in vitro (100 nM) greatly inhibited
the Nic-induced overflow of GABA (70%), Glu (85%), and Asp
(70%), whereas all the other concentrations (10 nM, 1 nM,
100 pM) were ineffective. Therefore, in vitro the Nic-induced
GABA overflow was not potentiated by low concentrations of the
peptide, as observed in vivo. The inhibitory effect was specific for
Ab1–40 since the reverse peptide (Ab40–1) at the same
concentration (100 nM) did not modify the Nic-stimulated release
of all three neurotransmitters (Fig. 5).
Parallel to in vivo experiments, we also evaluated the effect of
Ab1–40 on the transmitter release stimulated by Ver in vitro.
10 mM Ver stimulated an overflow of GABA that was
836.816124.66 pmol mg
21 protein (Fig. 6A). In regard to
excitatory neurotransmitters, the Ver-induced overflow of Glu
and Asp was 1039.286174.84 and 179.26624.49 pmol mg
21
protein, respectively (Fig. 6B). Similarly to the in vivo results, also in
vitro Ab1–40 (tested at 100 pM and 100 nM, thus at the lowest and
highest concentration that had been evaluated on synaptosomes)
did not modify the release of GABA, Glu, and Asp that was
stimulated by a depolarizing stimulus such as Ver (Fig. 6).
Moreover, we also evaluated the effects of Ab1–40 on another
depolarizing secretory stimulus such as potassium (K
+). 12 mM K
+
evoked an overflow of GABA, Glu and Asp that was
694.006144.00, 827.006158.00, 102.00615.00, respectively.
Figure 6 shows that 100 nM Ab1–40 did not modify the K
+-
induced release of GABA, Glu and Asp.
Our in vitro method (i.e., synaptosomes in superfusion), permits
us to unequivocally identify the receptor targeted by specific drugs
and anatomically localize it onto a precise synaptosomal
population, and to pharmacologically characterize it [30].
Moreover, the possibility that the evoked release of Glu, Asp
and GABA may influence the release of other measured
neurotransmitters can be almost totally excluded in our experi-
mental set up. Indeed, as previously described, synaptosomes are
plated as very thin layers on microporous filters and up-down
superfused with physiological solutions (see [30] and references
therein). Under these experimental conditions, the transmitters
released are removed by the superfusion fluid before they can
accumulate and activate presynaptic auto- and heteroreceptors, as
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e29661Figure 2. In vivo effect of different concentrations of beta-amyloid on the nicotine-induced overflow of hippocampal
neurotransmitters. Effect of beta-amyloid (Ab)1–40 (100 nM–10 mM) on 50 mM nicotine (Nic)-induced overflow of GABA (A), glutamate (Glu,
B) and aspartate (Asp, C). *p,0.05, **p,0.01, ***p,0.001 vs. Nic (One-way ANOVA followed by Dunnett’s Multiple Comparison Test). Data are
expressed as mean 6 SEM of 4–15 individual rats for each experimental group. Insets show the time course of 50 mM Nic-induced release of GABA (A
inset), Glu (B inset) and Asp (C inset). *p,0.05, **p,0.01 vs. basal release (One-way ANOVA followed by Bonferroni post hoc test). Data are
expressed as mean 6 SEM of 13–15 individual rats.
doi:10.1371/journal.pone.0029661.g002
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effects. Using this technique, we recently demonstrated that the
hippocampal release of GABA, Glu, and Asp is stimulated by the
activation of both a7 and a4b2 nAChRs at presynaptic level
[17,18]. Therefore, using the same experimental conditions, we
evaluated whether the effects of Ab1–40 on the Nic-evoked
overflow of GABA, Glu, and Asp may be mediated by either a7o r
a4b2 nAChRs or both. In order to do that, we first confirmed the
presence and functional effect of both a7 and a4b2 nAChRs on
glutamatergic and GABAergic hippocampal nerve endings by
using specific agonists. We chose choline (Ch) and 5-Iodo-A-85380
dihydrochloride (5IA85380) as selective agonists for a7 and a4b2,
respectively, and we administered them at the same concentration
used in our previous studies [17,18]. In regard to GABA, 1 mM
Ch evoked an overflow of 41.6963.46 pmol mg
21 protein that
was the same than that elicited by 10 nM 5IA85380
(40.4163.98 pmol mg
21 protein (Figures 7A and 7C). As far as
the excitatory neurotransmitters, both 1 mM Ch and 10 nM
5IA85380 evoked an overflow of Glu (61.0765.22 and
76.9168.86 pmol mg
21 protein respectively) and of Asp
(45.5263.16 and 56.1964.28 pmol mg
21 protein respectively)
(Figures 7B and 7D).
There was a dual effect of Ab1–40 on the release of
neurotransmitters evoked by Ch, the selective agonist for a7
nAChR subtype. 100 nM Ab1–40 (the highest concentration
considered in vitro) greatly inhibited the Ch-induced overflow of
GABA (45%), Glu (75%) and Asp (70%) (Figures 7A and 7B). On
the contrary, low concentrations of Ab1–40 (100 pM and 1 nM)
greatly enhanced (100% and 55%, respectively) the Ch-induced
Glu release (Fig. 7B). At 100 pM (the lowest concentration
considered in vitro)A b1–40 also potentiated (55%) the Asp release
evoked by 1 mM Ch (Fig. 7B). The potentiating effect of low
concentrations of Ab1–40 was not observed in the case of GABA
release (Fig. 7A).
As far as the a4b2-selective agonist, 100 nM Ab1–40 (the
highest concentration considered in vitro) greatly inhibited the
5IA85380-induced overflow of all three neurotransmitters
(GABA=60%; Glu=70%; Asp=85%) (Figures 7C and 7D). All
the other concentrations were ineffective.
Discussion
In the present work we found for the first time that Ab1–40
affects in vivo and in vitro the nicotinic-control of the hippocampal
release of GABA, Glu, and Asp, in absence of gross signs of
neurodegeneration.
Some strategies let us to avoid neurotoxic effects of the
peptide. First, the study was focused on Ab1–40 since it is the
most abundant form that is present in physiological state. In
fact, the concentration of secreted Ab1–42 is about 10% that of
Ab1–40 [31]. Moreover, Ab1–40 and Ab1–42 have different
profiles of aggregation [32]. Ab1–40 has been reported to
aggregate more slowly than Ab1–42; therefore, the latter is
considered as the most neurotoxic species [24]. On the other
hand, in our previous in vivo experiments in nucleus accumbens,
at variance with Ab1–40, Ab1–42 was ineffective since it was
retained inside the dialysis probe and did not reach the brain
tissue, as shown by immunohistochemical analysis [5]. We
subsequently administered a freshly prepared solution of Ab1–
40 in order to minimize its aggregation. Finally, we used a
dialysis membrane with a cutoff size of 40 KDa to allow the
passage through the dialysis fiber of soluble Ab monomers or
small molecular weight oligomers and avoid high molecular
weight oligomers (the neurotoxic species as shown by [33]). In
our experimental conditions, the peptide did not aggregate
(Fig. S1), therefore it did not give origin to neurotoxic oligo-
meric species.
Following the administration of different concentrations of
Ab1–40 (100 nM–10 mM), immunohistochemical analysis shows
that the peptide diffuses through the dialysis membrane to the
hippocampal tissue where it is found in proximity of the dialysis
probe (Fig. 1). No apoptotic-related phenomena were observed
within the area of amyloid diffusion as shown by Hoechst staining.
However, we cannot exclude the presence, even at this early time,
after Ab treatment, of more subtle signs of toxicity such as synaptic
degeneration and neurite retraction.
Figure 3. Lack of effect of beta-amyloid on the veratridine-
induced neurotransmitter release in hippocampus in vivo. Effect
of beta-amyloid (Ab)1–40 (100 nM and 10 mM) on 100 mM veratridine
(Ver)-induced overflow of GABA (A), glutamate (Glu, B) and aspartate
(Asp, C). (One-way ANOVA followed by Dunnett’s Multiple Comparison
Test). Data are expressed as mean 6 SEM of 4 individual rats for each
experimental group. Insets show the effect of two different concentra-
tions of Ver (50 mM and 100 mM) on the release of GABA (A inset), Glu
(B inset) and Asp (C inset). **p,0.01 vs. Basal (One-way ANOVA
followed by Dunnett’s Multiple Comparison Test). Data are expressed as
mean 6 SEM of 4–9 individual rats for each experimental group.
doi:10.1371/journal.pone.0029661.g003
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Ab1–40 and dual effects on GABA release
We observed both in vivo and in vitro that high concentrations of
Ab1–40 (10 mM and 100 nM, the two highest concentrations
respectively used in vivo and in vitro) greatly inhibit the Nic-induced
release of GABA, Glu, and Asp in the hippocampus (Figures 2 and
5). The observed inhibitory effect is consistent with that previously
described in the nucleus accumbens and striatum at similar
concentrations when studying dopamine and GABA release [5–7].
The inhibitory effect on Glu and Asp but not on GABA release
was observed also using lower in vivo concentrations (1 mM) of
administered Ab (Fig. 2). Surprisingly enough, in vivo 100 nM
Ab1–40 (the lowest concentration considered) was able to
potentiate the GABA overflow evoked by 50 mM Nic (Fig. 2).
To our knowledge, this is the first demonstration of the Ab1–40
capability to modulate both positively and negatively the nicotinic
cholinergic control of GABA release in vivo. The observed dual
effect of the peptide is in line with the hypothesis that Ab may have
different biological effects increasing the concentrations, possibly
in a continuum from physiology to pathology [4]. Interestingly,
100 nM Ab1–40 potentiates the Nic-induced GABA release
(function), 1 mMA b1–40 is ineffective (loss of function) and
10 mMA b1–40 has an inhibitory effect (gain of new function). The
dual effect of Ab on Nic-induced GABA release was not
appreciated in vitro.
Figure 4. Time course of nicotine and beta-amyloid evoked GABA (A), glutamate (B) and aspartate (C) release in vitro. Synaptosomes
were depolarized with nicotine (Nic) or beta-amyloid (Ab)1–40 for 90 s at t=38 min of superfusion (black bar). Values represent mean 6 SEM of at
least eight replicate superfusion chambers per condition (basal or evoked release). *p,0.05, **p,0.01 vs. GABA basal release;
#p,0.05;
##p,0.01 vs.
glutamate (Glu) basal release;
uup,0.01 vs. aspartate (Asp) basal release. Two way ANOVA followed by Bonferroni post hoc test.
doi:10.1371/journal.pone.0029661.g004
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reasons. First, in vivo concentrations are higher than those used in
vitro in order to guarantee the delivery to the tissue of sufficient
amount of drugs. Despite the fact that immunohistochemical
micrographs (Fig. 1) show that there is a positive correlation
among the Ab concentrations administered and the amount of
immunostaining in the hippocampal tissue, we do not know the
exact amount of Ab that reaches the tissue during a microdialysis
experiment and its accumulation/disposal with time. Another
difference between the two experimental models is the timing of
exposure to experimental drugs (few seconds in vitro versus
40 minutes in vivo). Moreover, the observation of an in vivo
potentiating effect of low concentrations of Ab on the Nic-induced
GABA release may be explained by indirect mechanisms of
control of neurotransmitter release present in vivo. In fact, the levels
of both excitatory and inhibitory neurotransmitters measured in
vivo are the final result of the interactions of hierarchically
organized synapses ultimately controlling Glu, Asp, and GABA
release. In this regard, the in vivo GABA increase mediated by low
concentrations of Ab could be due to an indirect modulatory role
Figure 5. In vitro effect of beta-amyloid on the nicotine-induced overflow of hippocampal neurotransmitters. Effect of different
concentrations of beta-amyloid (Ab)1–40 on the nicotine (Nic)-induced overflow of endogenous GABA (A), glutamate and aspartate (Glu and Asp
respectively, B) from rat hippocampal synaptosomes. Synaptosomes were depolarized with Nic for 90 s at t=38 min of superfusion. When
appropriate Ab was introduced 8 min before Nic. Data are mean 6 SEM of 5–8 experiments run in triplicate. ***p,0.001 vs. Nic-evoked GABA
overflow;
###p,0.001 vs. Nic-evoked Glu overflow;
uuup,0.001 vs. Nic-evoked Asp overflow. One way ANOVA followed by Dunnett post hoc test.
doi:10.1371/journal.pone.0029661.g005
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concentrations potentiate the release of Glu and Asp from
synaptosomes,whichmightinturnstimulateGABA releasethrough
the activation of glutamatergic receptors on GABAergic neurons
[34]. On the contrary, indirect control mechanisms of neurotrans-
mitter release are excluded in our in vitro model of synaptosomes in
superfusion. In fact, in vitro data obtained on perfused synaptosomes
are due to the direct effects of the added drugs, which have to act
upon receptors or modulatory sites located on the same synapto-
some from which occurs the release of the transmitter [30].
Effect of Ab on Glu, Asp and GABA release elicited by
depolarizing stimuli
In vivo and in vitro both low and high concentrations of the
peptide did not modify the overflow of Glu, GABA, and Asp that
was elicited by a depolarizing stimulus such as Ver (Fig. 3 and 6).
This observation is consistent with our previous in vivo and in vitro
data demonstrating that neurotransmitter release enhanced by
another depolarizing stimulus, such as K
+, was not affected by Ab
in two different brain areas [5,6], even if it should be mentioned
that Lee and Wang [35] and Kar and colleagues [36] (the latter
Figure 6. Lack of effect of beta-amyloid on both potassium- and veratridine-induced neurotransmitter release in hippocampus in
vitro. Effect of different concentrations of beta-amyloid (Ab)1–40 on both potassium (K
+)- and veratridine (Ver)-evoked overflow of endogenous
GABA (A), glutamate and aspartate (Glu and Asp respectively, B) from rat hippocampal synaptosomes. Synaptosomes were depolarized either with
Ver or with K
+ for 90 s at t=38 min of superfusion. When appropriate Ab was introduced 8 min before Ver or K
+. Data are mean 6 SEM of 3–6
experiments run in triplicate.
doi:10.1371/journal.pone.0029661.g006
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concentrations. Ver is a lipid-soluble neurotoxin that is an
activator of Na
+ channels. It targets the neurotoxin receptor site
2 and preferentially binds to activated Na
+ channels causing
persistent activation [37]. This persistent Na
+ induces bursts of
action potentials and sustains membrane depolarization, which is
subsequently correlated with an opening of voltage-gated Ca
2+
channels [38]. The final result is the enhancement of neurotrans-
mitter release [39]. In our experimental setting, the lack of effect of
Ab on Ver stimulus suggests that Ab1–40 may affect the Nic-
triggered neurotransmitter release directly binding to nAChRs or
acting to substrates that are specific for nAChRs-induced
intracellular signaling. The action is specific for Ab1–40 sequence
since the reverse peptide was ineffective (Fig. 2 and 5).
In vitro pharmacological dissection of the effect of Ab on
Glu, Asp and GABA release elicited by specific nicotinic
agonists
Another possible explanation for the differences of Ab effect on
GABA release observed in vivo (dual effect) and in vitro (inhibition
only) may depend on the differential contribution to the described
effect of a7 and a4b2 nAChRs. This aspect was approached in vitro
by using specific nicotinic agonists. We previously demonstrated
that hippocampal glutamatergic and GABAergic nerve endings
show both a7 and a4b2 nAChRs that are capable to control
neurotransmitter release [17,18]. The reported results show that
the stimulation of both a7 and a4b2 nAChRs elicits the release of
Asp, Glu, and GABA, thus indicating that both receptors are
positively linked to the release of the studied neurotransmitters,
even if it is possible that they reside on different nerve endings
populations and that they operate through distinct cellular
mechanisms [40]. At high concentrations (100 nM), Ab is always
inhibitory on the release stimulated by both Ch (a7 selective
agonist) and 5IA85380 (selective for a4b2 nAChRs) (Fig. 7). On
the contrary, low concentrations of Ab1–40 (1 nM and 100 pM)
selectively act on a7 subtypes potentiating the Ch-induced release
of both Asp and Glu (Fig. 7B), but not the one elicited by
5IA85380. Therefore, we were able to observe dual effects of Ab in
vitro when using specific nAChRs agonists. However, somewhat
surprisingly, the stimulatory activity of low Ab concentrations was
associated with Glu and Asp and not with GABA release, as
expected. Interestingly, some papers show that the physiological
range of concentrations of the peptide is from pM to low nM
[41,42]. Hence, the relevance of our data to AD is that high, likely
not physiological, concentrations of Ab greatly impair cholinergic
Figure 7. In vitro effect of beta-amyloid on hippocampal neurotransmitter release elicited by specific nicotinic agonists. Effect of
different concentrations of beta-amyloid (Ab)1–40 on choline (Ch)-evoked overflow of endogenous GABA (A), glutamate and aspartate (Glu and Asp
respectively, B) and on the 5IA85380-evoked overflow of endogenous GABA (C), Glu and Asp (D) from rat hippocampal synaptosomes.
Synaptosomes were depolarized either with Ch or with 5IA85380 for 90 s at t=38 min of superfusion. When appropriate Ab was introduced
8 min before the specific nicotinic agonist. Data are mean 6 SEM of 3–6 experiments run in triplicate. **p,0.01 vs. Ch-evoked GABA overflow;
#p,0.05,
###p,0.001 vs. Ch-evoked Glu overflow;
uup,0.01,
uuup,0.001 vs. Ch-evoked Asp overflow.
$$p,0.01 vs. 5IA85380-evoked GABA overflow;
c ¸c ¸c ¸p,0.001 vs. 5IA85380-evoked Glu overflow;
o `o `o `p,0.001 vs. 5IA85380-evoked Asp overflow. One way ANOVA followed by Dunnett post hoc test.
doi:10.1371/journal.pone.0029661.g007
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contrary, physiological concentrations of the peptide may po-
tentiate the positive nicotinic control of neurotransmitter release,
specifically acting on a7 subtypes. This last observation is con-
sistent with some data showing the capability of picomolar Ab to
activate a7 receptors currents [43]. This view contrasts with the
fact that we did not observe an impact of Ab on basal neu-
rotransmitter release from synaptosomes. On the other hand, the
possibility of a direct activation on a7 receptors by the peptide is
consistent with the demonstration that a low picomolar concen-
tration of Ab enhances hippocampal long term potentiation (LTP)
and memory with a mechanism dependent upon activation of a7
nAChRs [44]. Interestingly, Puzzo and collaborators also showed
that, physiologically, the presence of the peptide is required for the
modulation of LTP and memory formation in a mechanism
dependent on a7 nAChRs [45].
Our data show that low concentrations of Ab (100 pM and
1 nM) seem to selectively modulate a7-depending functions
whereas 100 nM Ab interacts with both receptors subtypes
negatively affecting their function. In this regard, Wang and
collaborators [8] showed that the peptide can bind with picomolar
affinity to a7 subtypes and with 100–5000 times lower affinity to
a4b2 nAChRs, suggesting that, in our experimental conditions, a
possible mechanism of action of Ab concerns the physical inter-
action to nAChRs. Particularly, it seems that Ab binds nAChRs
near the nicotine binding site [46]. However, it has also been
hypothesized that Ab influences the function of a7 subtype by
altering the packing of lipids within the plasma membrane, instead
of directly binding to the receptors [47]. Since some authors have
shown the capability of neurons to internalize Ab [48], it cannot
be excluded that the peptide may enter synaptosomes and act on
cytosolic substrates downstream nAChRs.
Our results are at partial variance with those published by
Mehta and colleagues [49] showing that in the hippocampus low
concentrations of Ab1–42 increase pre-synaptic Ca
++ through the
action on a4b2 nAChRs, whereas in cortex the involved receptors
are mainly the a7 subtypes. The two experimental models,
however, are too different to allow a direct comparison. Mehta
and colleagues used knockout mice (C57Bl/6J) to demonstrate the
selective involvement of nAChRs and measured intrasynaptoso-
mal calcium fluxes, while we measured the release of transmitters
altered by the treatment with Ab1–40 using Wistar rat syn-
aptosomes. As already discussed, in our case we also observed
important differences between in vivo (in a ‘‘wired’’ system) and in
vitro experiments. Moreover, it is possible that in knockout mice
adaptive phenomena take place with time. In spite of so many
differences, it is noteworthy that both our data and those by Mehta
and collaborators agree on the possibility that low concentrations
of Ab peptides may stimulate synaptosomal activity through the
interaction with nAChRs. Both sets of data show that Ab peptides
may act differently on a4b2 and a7 nAChRs depending on the
adopted experimental settings. Interestingly, when using hyppo-
campal synaptosomes derived from non-transgenic rats the same
group of Mehta found that picomolar Ab directly activates
presynaptic a7 nAChRs to increase nerve terminal Ca
2+ [50] in
line with our results.
In regard to the functional effect of the peptide, the dual action
of low and high Ab concentrations on a7-mediated neurotrans-
mitter release may be explained by different ways. First, a
desentization-related mechanism, as concentrations of Ab1–40 in
the range 10 pM–1 nM have been reported to activate a7
nAChRs, whereas an higher concentration (100 nM) induces
desentization of the receptor [43]. Moreover, increasing the
concentrations Ab may change its targets. In fact, at low
concentrations Ab can selectively activate a7 nAChRs. However,
at high concentrations the peptide may act simultaneously on
different targets, possibly downstream nAChRs, leading to the
oxidative modification of synaptosomal proteins [51] and perhaps
to an inhibitory action on neurotransmitter release.
The lack of potentiating effect of low Ab concentrations on in
vitro GABA release elicited by Ch further supports the idea that the
in vivo observed potentiation is due to indirect mechanisms
involving a neuronal circuit. On the other hand, it is difficult to
explain why low Ab concentrations potentiate the a7-stimulated
release of Glu and Asp, but not the one of GABA. One possibility
is that the synaptosomal release machinery of Glu, Asp, and
GABA recruited by a7 stimulation differ, as suggested in the case
of the sensitivity of glutamatergic and GABAergic release to
botulin toxins [52]. Alternatively, it is either possible that variants
of a7 receptors [53] may control the release of Glu, Asp, and
GABA, or that the differential pacing in the desensitization
mechanism of the nAChRs residing on Glu, Asp, and GABA
terminals may affect the action of Ab.
Conclusions
Altogether, the results reinforce the concepts that Ab has
relevant neuromodulatory effects, which may span from facilita-
tion to inhibition of stimulated release depending upon the
concentration. Of particular interest is the observation that, at
least in vitro, the nicotinic cholinergic control of two excitatory
neurotransmitters, Asp and Glu, was particularly sensitive to the
effect of low Ab concentrations in synaptosomes derived from the
hippocampus. Moreover, the involved receptor seems to be the a7
one, which other lines of evidence suggest to be a target of Ab.
These actions may be relevant to the early stages of AD which,
rather than being characterized by neurodegeneration, may be
associated with synaptic dysfunctions affecting more than a
transmitter system, albeit with peculiar sensitivity of mechanisms
associated with nicotinic cholinergic transmission. It may be
hypothesized that the early derangement of Ab production may
lead to trespass the threshold beyond which Ab loses the ability to
co-promote Asp and Glu release, which may be linked to an
efficient memory trace formation, and subsequently gains the
ability to directly inhibit the ability of cholinergic stimuli to
promote Glu and Asp release. This may further impair the signal
to noise ratio of Glu transmission associated with synaptic trace
formation. The neurotoxicity may finally eventually become the
leading event. Moreover, parallel to this impairment of cholinergic
control of Glu and Asp release, other effects may be present in
other brain areas involving other neurotransmitters, thus provid-
ing the basis for a multitransmitter deficit in the disease. This is
turn may be responsible for the various psychiatric symptoms that
characterize subsets of patients, in addition to the more easily
recognized memory deficits. These observations may help to
redirect the pharmacological approaches toward multiple neuro-
transmitter targets in the early stages of the disease.
Materials and Methods
Chemicals
5-Iodo-A-85380 dihydrochloride (3-[(2S)-2-Azetidinylmethoxy]-
5-iodopyridine dihydrochloride) was purchased from Tocris
Bioscience (Bristol, UK); nicotine hydrogen tartrate salt, veratri-
dine, Ab1–40 and Ab40–1, PercollH, Choline Iodide, dimethyl
sulfoxide were obtained from Sigma Aldrich (Milan, Italy); all salts
used for the preparation of artificial cerebrospinal fluid (aCSF)
(NaCl, KCl, CaCl2, MgCl2,N a 2HPO4) and for Equithesin
(MgSO4) were purchased at Merck KGaA, Darmstadt, Germany;
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the preparation of Equithesin and were obtained at VWR BDH
Prolabo, Belgium.
Preparation of Ab1–40 solutions
In the case of both in vivo and in vitro experiments, synthetic
human Ab1–40 (Sigma Aldrich, Milan, Italy) was dissolved in
aCSF at a concentration of 100 mM (stock solution). Then, this
solution was filtered through a Millipore 0.2 mm pore membrane
and stocked in small aliquots at 280uC. Working solutions were
freshly prepared by diluting an aliquot of Ab1–40 stock solution at
the final concentrations (10 mM, 1 mM, or 100 nM Ab1–40 for in
vivo experiments, 100 nM, 10 nM, 1 nM, or 100 pM for in vitro
analysis).
Animals
Young male Wistar rats (275–300 g; Harlan, Udine Italy),
housed in standard conditions (temperature 2361uC; humidity
50%) with 12:12 light/dark cycles, water and food ad libitum, were
used either for microdialysis experiments or as brain tissue source
for the in vitro experiments. The use of animals for the preparation
of synaptosomes was approved by the Ethical Committee of the
Pharmacology and Toxicology Section, Department of Experi-
mental Medicine, in accordance with the European legislation
(European Communities Council Directive of 24 November 1986,
86/609/EEC) and were approved by Italian legislation on animal
experimentation (Decreto Ministeriale number 124/2003-A). The
in vivo protocol was approved by Ethical Committee of Pavia’s
University (registered as 2/2008) according to international
regulations for the care and treatment of laboratory animals, to
the Italian Act (DL n 116, GU, suppl 40, 18 February, 1992) and
to EEC Council Directive (86/609, OJ L 358, 1, 12 December,
1987). All efforts were made to minimize animal suffering and to
use the minimal number of animals necessary to produce reliable
results.
In vivo experiments
Microdialysis probe implantation. Rats were anesthetized
with Equithesin 3 ml/kg (pentobarbital 9.7 g, chloral hydrate
42.5 g, MgSO4 21.3 g for 1 L, 10% ethanol, 40% propylene
glycole v/v) administered intraperitoneally and placed in a
stereotaxic apparatus (David Kopf Instruments, Tujunga, CA,
USA). The skin was shaved, disinfected, and cut with a sterile
scalpel to expose the skull. A hole was drilled to allow the
implantation of the probe into the brain parenchyma. The probe
was implanted in the hippocampus (CA1/CA2 regions; AP
25.8 mm, ML 65.0 mm from bregma and DV–8.0 mm from
dura, according to [54]) and secured to the skull with one stainless
steel screw and dental cement. All experiments were performed
using microdialysis probes, made in our laboratory according to
the original method described by Di Chiara and colleagues [55]
(Emophan Bellco Artificial OR-internal diameter 200 mm, cutoff
40 KDa; Bellco, Mirandola, Italy), with a nominal active length of
5 mm.
Finally, the skin was sutured, and the rats were allowed to
recover from anesthesia.
Microdialysis samples collection. Microdialysis experi-
ments were performed on conscious freely moving rats. On the
day of the experiments (24 hours after the surgical procedure), the
probe was perfused with aCSF containing 145 mM NaCl,
3.0 mM KCl, 1.26 mM CaCl2, 1.0 mM MgCl2, 1.4 mM
Na2HPO4, buffered at pH 7.2–7.4 and filtered through a
Millipore 0.2 mm pore membrane. In all experiments, the
microdialysis membrane was allowed to stabilize for 1 hour at
the flow rate of 4 ml/min, without collecting samples. At the end of
the stabilization period, three samples were collected to evaluate
baseline release of GABA, Asp, and Glu; then, the specific
treatment started. In the case of Ab administration, a pre-
treatment of 20 min with the peptide preceded its co-perfusion
either with Nic or with Ver. Anyway, the perfusion of the peptide
did not last more than 100 min. All treatments were administered
by manually switching syringes and tubing connections to allow
drugs diluted in aCSF to flow through the probes. Tubing switches
were performed taking care to maintain constant flow rates and
collection volumes. Both basal and treatment samples were
collected every 20 min in 100 ml Eppendorf tubes at a flow rate
of 4 ml/min, using a 1000 ml syringe (Hamilton) and a micro-
injection pump (CMA/100, CMA/Microdialysis AB). Levels of
GABA, Glu and Asp in the dialysate were measured by high
performance liquid chromatography (HPLC) with fluorometric
detection (see Chromatography). In vitro recovery of the dialysis
probe was 13.8860.25 for Asp, 15.2160.42 for Glu and
7.9160.25 for GABA. Each rat was used for only one
microdialysis session. At the end of each experiment, animals
were sacrificed by guillotine, rat brains were removed, and the
position of the microdialysis probe was verified by histological
procedures, slicing the tissues by a cryostat microtome (LEICA
CM 1510). Only data from rats in which probe tracks were exactly
located in the target area were used for statistical analysis.
In vitro experiments
Experiments of release. Rats were killed by decapitation
and the hippocampus was rapidly removed at 0–4uC. Purified
synaptosomes were prepared on PercollH gradients (Sigma-
Aldrich, St Louis, MO, USA) according to the original method
described by Dunkley et al., [56], with only minor modifications.
Briefly, the tissue was homogenized in 6 volumes of 0.32 M
sucrose, buffered at pH 7.4 with Tris–HCl, using a glass-teflon
tissue grinder (clearance 0.25 mm, 12 up–down strokes in about
1 min). The homogenate was centrifuged (5 min, 1000 g at 4uC)
to remove nuclei and debris; the supernatant was gently stratified
on a discontinuous PercollH gradient (2%, 6%, 10%, and 20% v/v
in Tris-buffered sucrose) and centrifuged at 33500 g for 5 min at
4uC. The layer between 10% and 20% PercollH (synaptosomal
fraction) was collected, washed by centrifugation and resuspended
in physiological HEPES-buffered medium having the following
composition (mM): NaCl 128, KCl 2.4, CaCl2 3.2, KH2PO4 1.2,
MgSO4 1.2, HEPES 25, pH 7.5, glucose 10, pH 7.2–7.4 [57].
Synaptosomal protein content following purification was 10–15%
of that in the supernatant stratified on the PercollH gradient.
The synaptosomal suspension was layered on microporous
filters at the bottom of a set of parallel superfusion chambers
maintained at 37uC [30] (Superfusion System, Ugo Basile,
Comerio, Varese, Italy). Synaptosomes were superfused at 1 ml/
min with standard physiological medium as previously described.
The system was first equilibrated during 36.5 min of superfusion;
subsequently, four consecutive 90 s fractions of superfusate were
collected. Synaptosomes were exposed to agonists for 90 s starting
from the second fraction collected (t=38 min), with antagonists
being added 8 min before agonists. We have previously amply
demonstrated that in our superfusion system the possible effects of
drugs operated indirectly by other mediators in the monolayer of
synaptosomes in superfusion are absolutely minimized [30].
Chromatography
In both dialysates and fractions collected from synaptosomes in
superfusion levels of endogenous GABA, Glu, and Asp were
measured by HPLC analysis following precolumn derivatization
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chromatographic column (1064.6 mm, 3 mm; Chrompack, Mid-
dleburg, The Netherlands) coupled with fluorometric detection
(excitation wavelength 350 nm; emission wavelength 450 nm).
Homoserine was used as internal standard. Buffers and gradient
program were prepared and executed as follows: solvent A, 0.1 M
sodium acetate (pH 5.8)/methanol, 80:20; solvent B, 0.1 M sodium
acetate (pH 5.8)/methanol, 20:80; solvent C, sodium acetate
(pH 6.0)/methanol, 80:20; gradient program, 100% C for 4 min
from the initiation of the program; 90% A and 10% B in 1 min;
42% A and 58% B in 14 min; 100% B in 1 min; isocratic flow
2 min; 100% C in 3 min; flow rate 0.9 ml/min.
Immunohistochemical analysis
Immunohistochemical analysis was performed to verify the
presence of Ab in the perfused tissue and to confirm (according to
HOECHST 33342 staining) the absence of neurotoxic-induced
apoptotic phenomenon. Brain tissue samples were frozen and
stored at 280uC. For immunodetection of infused Ab peptide,
10 mm coronal sections (obtained on a cryostat Leica CM 1510)
were incubated with a primary monoclonal antibody recognizing
Ab protein (clone 4G8; Chemicon International). Sections were
then incubated with a mouse anti-IgG antibody RPE conjugated
(Dako). After the fluorescent labeling procedures, sections were
finally counterstained for DNA with HOECHST 33342 and
mounted in a drop of Mowiol (Calbiochem, Inalco SpA, Milan,
Italy). Fluorescent micrographs were acquired with a Leica TCS
SP5 II confocal microscope. After acquisition of fluorescent
micrographs, the slides were demounted and then the same
sections were slightly counterstained with Mayer hematoxylin,
dehydrated and mounted in DPX for microanatomical analysis.
The images were acquired with a BX51 Olympus microscope.
Western blotting procedure
Samples were subjected to SDS-PAGE (15%) and then
transferred onto PVDF membrane (DuPont NEN, Boston MA).
The membrane was blocked for 1 hour with 5% non fat dry milk
in Tris-buffered saline containing 1% Tween 20 (TBST).
Membranes were immunoblotted with the antibody 6E10,
recognizing residues 1–17 of Ab (Chemicon-Prodotti Gianni,
Milano, Italy). The detection was carried out by incubation with
horseradish peroxidase conjugated goat anti-mouse IgG (Kirke-
gaard and Perry Laboratories, Gaithersburgh, MD U.S.A.) for
1 h. The blots were then washed extensively and Ab visualized
using an enhanced chemiluminescent methods (Pierce, Rockford,
IL, USA). Molecular mass was estimated by molecular weight
markers (Invitrogen).
Statistical analysis
In vivo experiments. Values were expressed either as
amount of neurotransmitter measured in the dialysate (pmol/
80 mL) or as area under the curve (AUC), evaluating the
cumulative release over time. AUC was used as a measure of
treatment exposure and was calculated for each animal using
GraphPad Prism (version 4.03 GraphPad Software, San Diego,
CA, USA). The basal value (average concentration of three
consecutive samples immediately preceding the drug dose) was
used as baseline to calibrate the calculation.
D’Agostino-Pearson Omnibus Test (GraphPad Prism, version
4.03, GraphPad Software, San Diego, CA, USA) and Grubb’s
Test (GraphPad QuickCalcs, online calculator for scientists at
http://www.graphpad.com/quickcalcs/, GraphPad Software, San
Diego, CA, USA) were used as preliminary tests in order to
evaluate whether data were sampled from a Gaussian distribution
and to detect outliers respectively. All outliers were excluded from
the analysis. Data were analyzed by analysis of variance (ANOVA)
followed, when significant, by an appropriate post hoc comparison
test. Data were considered significant for p,0.05. The reported
data are expressed as means 6 S.E.M. The number of animals
used for each experiment is reported in the legend to Figures 2 and
3.
In vitro experiments. The evoked overflow was calculated
by subtracting the corresponding basal release from each fraction.
All data are expressed as pmol?mg
21 protein and represent mean
6 SEM of the number of experiments reported in the figure
legends. Multiple comparisons were performed with one-or two
way ANOVA followed by an appropriate post hoc test (Dunnett or
Bonferroni). Data were considered significant for p,0.05 at least,
using KyPlot 2.0 beta 15.
Supporting Information
Figure S1 Characterization of beta-amyloid (Ab) con-
formation by using Western Blot procedure. SDS-PAGE
showing immunoreactive species consistent with Ab monomer in
all the preparations analyzed: the stock solution (100 mMA b1–40)
freshly prepared, the stock solution (100 mMA b1–40) maintained
for 100 min at room temperature and the most concentrated
working solution evaluated in vivo (10 mMA b1–40) maintained for
100 min (maximum length of Ab1–40 perfusion during micro-
dialysis experiments) at room temperature.
(TIF)
Figure S2 Lack of effect of beta-amyloid on the basal
neurotransmitter release in hippocampus in vivo. Effect
of beta-amyloid (Ab)1–40 (100 nM–10 mM) on the basal release of
GABA (A), glutamate (Glu, B) and aspartate (Asp, C). One-way
ANOVA. Data are expressed as mean 6 SEM of 4–9 individual
rats for each experimental group.
(TIF)
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